A Phase 1 clinical trial of a new drug targeting uveal melanoma showed measurable anti-tumor activity in patients, according to a report by Ophthalmology Times Europe. The findings are considered a meaningful early signal for a cancer that has historically been difficult to treat once it spreads beyond the eye.
Uveal melanoma is a rare form of melanoma that originates in the uveal tract, which includes the iris, ciliary body, and choroid of the eye. It is the most common primary intraocular malignancy in adults. While localized disease can often be treated with radiation or surgery, metastatic uveal melanoma responds poorly to most of the therapies that have been effective against other forms of melanoma. Patients whose cancer has spread face a particularly limited set of options.
Phase 1 trials are designed primarily to assess safety and determine appropriate dosing rather than to prove that a drug works. That makes any evidence of anti-tumor activity at this stage notable. The report indicated that researchers observed measurable tumor reduction in some participants, suggesting the drug is reaching its target and producing a biological response.
The report did not specify the name of the drug or the number of patients enrolled in the trial. Phase 1 studies typically involve small numbers of participants, and results at this stage do not yet indicate how the drug will perform in larger, more rigorous trials. Researchers will need to advance through Phase 2 and Phase 3 testing before the drug could be considered for regulatory approval.
Uveal melanoma affects an estimated 2,000 to 2,500 people in the United States each year. Despite its relative rarity, it draws significant research attention because of the lack of effective treatments for advanced disease and because its genetic and biological characteristics differ substantially from cutaneous melanoma, the more common skin-based form of the cancer.
The Phase 1 findings are expected to inform the design of future trials as researchers work to establish optimal dosing and identify which patients may be most likely to benefit from the treatment.
